任詩(shī)松,黃 斌,劉輝均
·臨床醫(yī)學(xué)·
·論著·
股骨近端防旋髓內(nèi)釘手術(shù)治療對(duì)老年股骨粗隆間骨折患者骨代謝和骨強(qiáng)度的影響
任詩(shī)松,黃 斌,劉輝均
目的探討股骨近端防旋髓內(nèi)釘手術(shù)(PFNA)治療對(duì)老年股骨粗隆間骨折患者骨代謝和骨強(qiáng)度的影響。方法選擇2014年1月至2015年8月醫(yī)院收治的老年股骨粗隆間骨折患者50例為觀察組對(duì)象,另在醫(yī)院健康體檢處選擇50例無(wú)骨折病史的正常老年人作為對(duì)照組,對(duì)觀察組患者進(jìn)行PFNA治療,測(cè)定并比較手術(shù)前后觀察組患者和對(duì)照組正常老年人的骨代謝和骨強(qiáng)度指標(biāo)。結(jié)果手術(shù)前,觀察組患者骨代謝指標(biāo)中前膠原氨基末端前肽Ⅰ型(PINP)、甲狀旁腺激素(PTH)、Ⅰ型膠原羧基端肽(CTX)和血清骨鈣素(OC)水平均明顯高于對(duì)照組(均P<0.05),而25(OH)D3明顯低于對(duì)照組(P<0.05);手術(shù)后,觀察組患者血清PINP水平[(86.03±27.78)mg/L]較手術(shù)前[(53.97±26.13)mg/L]明顯升高(P<0.05);PTH水平[(27.67±11.54)ng/L]較手術(shù)前[(51.22±17.65)ng/L]明顯下降(P<0.05),略高于對(duì)照組[(36.85±12.86)ng/L](P>0.05),25(OH)D3、CTX和OC水平與手術(shù)前比較無(wú)明顯變化(均P>0.05)。手術(shù)前,觀察組患者股骨粗隆間區(qū)以及股骨頸區(qū)骨強(qiáng)度指標(biāo)中橫截面轉(zhuǎn)動(dòng)貫量(CSMI)、骨密度(BMD)和截面模量z值(Z)均比對(duì)照組低(均P<0.05),屈曲比率(BR)明顯高于對(duì)照組(P<0.05);手術(shù)后,觀察組患者骨強(qiáng)度指標(biāo)與手術(shù)前相比均稍有下降,但不具有統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論老年股骨粗隆間骨折患者經(jīng)PFNA治療后骨代謝增加,骨強(qiáng)度無(wú)明顯改變,可能由于手術(shù)中應(yīng)力遮擋作用而使髓內(nèi)釘周圍骨有少量丟失,需要加強(qiáng)抗骨質(zhì)疏松治療和防護(hù)措施以預(yù)防骨折。
股骨近端防旋髓內(nèi)釘手術(shù);老年;股骨粗隆間骨折;骨代謝;骨強(qiáng)度
老年股骨粗隆間骨折多是由髖部骨質(zhì)疏松所引起的,在外力作用下容易骨折,骨折后長(zhǎng)期臥床容易引發(fā)墜積性肺炎、泌尿系統(tǒng)感染、褥瘡等一系列并發(fā)癥,病死率高達(dá)15%~20%[1],通過(guò)股骨近端防旋髓內(nèi)釘手術(shù)(PFNA)治療股骨粗隆間骨折可使患者早期下床鍛煉,防止骨折并發(fā)癥的產(chǎn)生以降低患者死亡風(fēng)險(xiǎn)[2]。長(zhǎng)期以來(lái),對(duì)于髖部骨折的研究,包括骨強(qiáng)度以及骨代謝情況的變化,骨代謝生化指標(biāo)可早期反映出骨的轉(zhuǎn)換水平,是骨轉(zhuǎn)換過(guò)程中的代謝產(chǎn)物[3];在骨強(qiáng)度的研究中,人們更多關(guān)注是骨密度,能反映出骨礦鹽的含量信息,此外骨強(qiáng)度還包括股質(zhì)量的測(cè)定,諸如直徑、角度、面積等空間幾何分布屬性[4-5]。本研究擬對(duì)比分析無(wú)骨折人群以及老年骨粗隆間骨折患者手術(shù)前后骨強(qiáng)度和骨代謝指標(biāo),從而探討其與骨折風(fēng)險(xiǎn)的關(guān)系。
1.1 一般資料
選擇2014年1月至2015年8月第三軍醫(yī)大學(xué)第三附屬醫(yī)院收治的老年股骨粗隆間骨折患者50例為觀察組,其中男性18例,女性32例,年齡67~84歲,平均(75.43±6.58)歲,體質(zhì)指數(shù)為(23.46±2.86)kg/m2;另在武警重慶市消防總隊(duì)醫(yī)院健康體檢處選擇50例無(wú)骨折病史的正常老年人為對(duì)照組,其中男性19例,女性31例,年齡65~84歲,平均(76.24±5.96)歲,體質(zhì)指數(shù)為(24.03±3.02)kg/m2。2組入選者的性別、年齡、體質(zhì)指數(shù)差異無(wú)統(tǒng)計(jì)學(xué)意義(均P>0.05),具有可比性。
1.2 納入標(biāo)準(zhǔn)
(1)入選者年齡≥65歲;(2)觀察組患者均為跌倒所致的脆性骨折;(3)入選者均無(wú)肝/腎功能衰竭、類風(fēng)濕性關(guān)節(jié)炎、強(qiáng)直性脊柱炎、骨腫瘤、甲亢等其他影響骨代謝的疾病[6];(4)入選者入院前6個(gè)月內(nèi)均不曾使用降鈣素、二膦酸鹽、性激素等影響骨代謝的藥物;(5)觀察組患者手術(shù)指征良好,無(wú)手術(shù)禁忌證。
1.3 手術(shù)方法
觀察組患者均采用PFNA裝置進(jìn)行骨折內(nèi)固定方法,對(duì)患者進(jìn)行全身麻醉,通過(guò)C臂X線機(jī)透視以輔助牽引床復(fù)位,大轉(zhuǎn)子頂端作切口以暴露其尖端,在股骨髓腔內(nèi)進(jìn)導(dǎo)針,打開(kāi)股骨皮質(zhì),擴(kuò)髓后插入髓內(nèi)釘,于股骨頸中心處安裝近端套筒,11 mm空心鉆擴(kuò)孔,于股骨頭軟骨下連接并安裝螺旋刀片,遠(yuǎn)端固定,沖洗傷口,逐層縫合。手術(shù)后1 d積極鼓勵(lì)患者進(jìn)行早期練習(xí)活動(dòng),預(yù)防深靜脈血栓形成,改善血液循環(huán)促進(jìn)功能恢復(fù)[7]。每日服用600 mg碳酸鈣和0.5 mg活性維生素D,連續(xù)服用3個(gè)月。
1.4 觀察指標(biāo)
對(duì)手術(shù)前的觀察組和對(duì)照組及手術(shù)后3個(gè)月的觀察組分別進(jìn)行骨代謝、骨密度和骨強(qiáng)度指標(biāo)的測(cè)定。在骨代謝測(cè)定中,取空腹外周靜脈血,離心留取上層血清備用,采用美國(guó)Roche生產(chǎn)的E170全自動(dòng)電化學(xué)發(fā)光免疫分析系統(tǒng)和配套試劑盒檢測(cè)Ⅰ型前膠原氨基末端前肽(PINP)、甲狀旁腺激素(PTH)、25羥基維生素D3[25(OH)D3]、Ⅰ型膠原羧基端肽(CTX)和血清骨鈣素(OC);骨密度及骨強(qiáng)度測(cè)定中,采用Hologic Discovery A雙能X線骨密度儀(美國(guó)HOLOGIC),應(yīng)用骨密度分析軟件(APEX system software version 3.2)對(duì)髖關(guān)節(jié)股骨頸區(qū)骨密度(nnBMD)和股骨粗隆間區(qū)骨密度(itBMD)進(jìn)行測(cè)量;隨后采用配套的髖關(guān)節(jié)結(jié)構(gòu)分析軟件(HSA)分別測(cè)算出髖關(guān)節(jié)股骨粗隆間區(qū)以及股骨頸區(qū)骨強(qiáng)度指標(biāo):股骨頸區(qū)截面模量z值(nnZ)、股骨頸區(qū)橫截面轉(zhuǎn)動(dòng)貫量(nnCSMI)和股骨頸區(qū)屈曲比率(nnBR)、股骨粗隆間區(qū)橫截面轉(zhuǎn)動(dòng)貫量(itCSMI)、股骨粗隆間區(qū)截面模量z值(itZ)和股骨粗隆間區(qū)屈曲比率(itBR)。
1.5 統(tǒng)計(jì)學(xué)處理
各組骨代謝、骨密度和骨強(qiáng)度指標(biāo)用均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,應(yīng)用統(tǒng)計(jì)學(xué)軟件SPSS 20.0對(duì)數(shù)據(jù)進(jìn)行分析,組間比較采用t檢驗(yàn),P<0.05表示差異有統(tǒng)計(jì)學(xué)意義。
2.1 手術(shù)前后骨代謝變化
手術(shù)前,觀察組患者血清PINP、PTH、CTX和OC水平均明顯高于對(duì)照組(均P<0.05),而25(OH)D3明顯低于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。手術(shù)后,觀察組患者血清PINP水平較手術(shù)前明顯升高,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);PTH水平較手術(shù)前明顯下降,較對(duì)照組略高,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);25(OH)D3、CTX和OC水平與手術(shù)前比較無(wú)明顯變化,差異不具有統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表1。
表1 患者手術(shù)前后骨代謝變化(x±s,每組n=50)
注:PINP:Ⅰ型前膠原氨基末端前肽,PTH:甲狀旁腺激素,25(OH)D3:25羥基維生素D3,CTX:Ⅰ型膠原羥基端肽,OC:血清骨鈣素。與觀察組手術(shù)前比較aP<0.05;與對(duì)照組比較bP<0.05
2.2 手術(shù)前后骨強(qiáng)度變化
2.2.1 手術(shù)前后股骨頸區(qū)骨強(qiáng)度變化 手術(shù)前,nnBMD、nnCSMI和nnZ均明顯低于對(duì)照組(均P<0.05),nnBR明顯高于對(duì)照組(P<0.05);手術(shù)后,觀察組患者nnBMD、nnCSMI、nnZ和BR與手術(shù)前相比稍有下降,不具有統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表2。
表2 患者手術(shù)前后股骨頸區(qū)骨強(qiáng)度變化(x±s,每組n=50)
注:nnBMD:骰骨頸區(qū)骨密度,nnCSMI:橫截面轉(zhuǎn)動(dòng)貫量,nnZ:截面橫量Z值,nnBR:屈曲比率。與對(duì)照組比較aP<0.05
2.2.2 手術(shù)前后股骨粗隆間區(qū)骨強(qiáng)度變化 手術(shù)前,觀察組患者itBMD、itCSMI和itZ均明顯低于對(duì)照組(均P<0.05),itBR明顯高于對(duì)照組(P<0.05);手術(shù)后,觀察組患者itBMD、itCSMI、itZ和itBR與手術(shù)前相比稍有下降,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05)。見(jiàn)表3。
股骨粗隆間骨折常見(jiàn)于老年人,位于大粗隆及小粗隆之間,股骨粗隆部主要由松質(zhì)骨構(gòu)成,血管豐富,骨折后容易愈合,但容易產(chǎn)生髖內(nèi)翻[8]。老年人骨質(zhì)疏松、肢體不靈活,當(dāng)下肢突然扭轉(zhuǎn)、跌倒或使大粗隆直接觸地致傷,造成骨折,股骨粗隆部骨質(zhì)松脆,故骨折常為粉碎型,高齡患者長(zhǎng)期臥床引起的并發(fā)癥較多。年齡的增加會(huì)引起骨吸收增加,骨形成減少,骨量丟失,骨轉(zhuǎn)化出現(xiàn)負(fù)平衡,骨的結(jié)構(gòu)和形態(tài)出現(xiàn)改變并引起骨質(zhì)疏松[9-10]。本研究對(duì)比分析了無(wú)骨折史的正常老年人和老年股骨粗隆骨折患者骨密度、骨代謝以及骨強(qiáng)度等指標(biāo),探討其對(duì)骨折風(fēng)險(xiǎn)的評(píng)估價(jià)值。
表3 患者手術(shù)前后股骨粗隆間區(qū)骨強(qiáng)度變化(x±s,每組n=50)
注:itBMD:骨密度,itCSMI:橫截面轉(zhuǎn)動(dòng)貫量,itZ:截面模量Z值,itBR:屈曲比率。與觀察組手術(shù)前比較aP>0.05;與對(duì)照組比較bP<0.05
作為骨轉(zhuǎn)換過(guò)程中的代謝產(chǎn)物,骨代謝指標(biāo)能夠靈敏地反映出短期骨代謝障礙的情況,間接了解骨轉(zhuǎn)化和骨量變化的趨勢(shì),比骨密度更早反映出骨的轉(zhuǎn)換水平,不依賴骨密度檢查而預(yù)測(cè)骨折風(fēng)險(xiǎn)。PINP主要與骨細(xì)胞的活動(dòng)和骨形成有關(guān),反映了Ⅰ型膠原合成速率。正常骨組織中Ⅰ型膠原轉(zhuǎn)換率高于軟組織中,體內(nèi)含量較多。骨細(xì)胞合成出現(xiàn)減少時(shí),PINP下降,表明骨的形成減少。CTX是PINP的降解產(chǎn)物,正常人體中CTX含量較少,當(dāng)破骨細(xì)胞活性增強(qiáng)時(shí),PINP被大量降解并釋放到血中,PINP與CTX為首選骨轉(zhuǎn)換指標(biāo)[11]。本研究結(jié)果中,骨折患者PINP值與CTX值均明顯高于對(duì)照組,表明與骨折風(fēng)險(xiǎn)增高有關(guān)。作為一種維生素K依賴性鈣結(jié)合蛋白,OC由成骨細(xì)胞晚期分化合成,合成后部分釋放入血,血中OC含量反映了骨中維生素K的狀態(tài),是評(píng)價(jià)骨代謝的高靈敏性骨形成指標(biāo),用以預(yù)測(cè)髖部骨折的風(fēng)險(xiǎn)。本研究結(jié)果中,股骨粗隆骨折患者OC明顯高于無(wú)骨折史的正常老年人。骨折本身會(huì)引起OC增高,但OC增高很可能預(yù)示更高的骨折風(fēng)險(xiǎn)。PTH是一種鈣磷代謝平衡調(diào)節(jié)激素,正常人體中PTH的分泌呈規(guī)律的時(shí)相性,骨質(zhì)疏松患者PTH分泌紊亂,引起骨吸收或骨形成失衡,造成骨量丟失和骨結(jié)構(gòu)的改變[12]。因此PTH的變化可能預(yù)測(cè)骨質(zhì)疏松的發(fā)生風(fēng)險(xiǎn)。PTH反應(yīng)性增高,與骨折類型有關(guān),也可能與患者的預(yù)后有關(guān)[13]。術(shù)后補(bǔ)充碳酸鈣和維生素D,有利于促進(jìn)骨折愈合所需的鈣質(zhì)吸收,從而加快術(shù)后骨重建[14]。碳酸鈣含有骨骼發(fā)育的基本原料,而維生素D能夠促進(jìn)腸道對(duì)鈣的吸收,增強(qiáng)肌肉力量,降低骨質(zhì)疏松性骨折風(fēng)險(xiǎn)。25(OH)D3能夠準(zhǔn)確地反映人體內(nèi)維生素D的營(yíng)養(yǎng)狀況,本研究結(jié)果中25(OH)D3水平較低,有待進(jìn)一步更大樣本的臨床研究。
本研究中患者均為股骨粗隆間骨折,通過(guò)DXA測(cè)得的BMD值已被證實(shí)能夠很好地預(yù)測(cè)髖部骨折的風(fēng)險(xiǎn),但并不是骨力學(xué)性能理想地預(yù)測(cè)指標(biāo)。與常規(guī)的骨密度檢查相比,HSA可以獲取更多骨形態(tài)結(jié)構(gòu)方面的信息,了解某一特定橫截面骨的礦物質(zhì)信息和骨的幾何結(jié)構(gòu),能夠補(bǔ)充優(yōu)化BMD的不足[15]。當(dāng)CSMI值增加時(shí),骨的抗折彎能力也隨之增加,截面模量Z值反映了某一截面的彎曲強(qiáng)度,反映了某一截面在屈曲時(shí)所能承受的最大應(yīng)力,Z值越大,骨的抗折彎能力越強(qiáng)[16]。本研究中與未發(fā)生骨折人群相比,髖部骨折人群的截面模量顯著降低。生物力學(xué)中,BR過(guò)大會(huì)引起局部結(jié)構(gòu)的不穩(wěn)定,造成結(jié)構(gòu)破壞,對(duì)于骨組織即會(huì)引起骨折的發(fā)生[17]。BR值相比于Z值能更好的反映骨強(qiáng)度。研究結(jié)果中觀察組患者在股骨頸、股骨粗隆間兩個(gè)部位的骨密度BMD值、CSMI和Z值都小于對(duì)照組,而屈曲比率高于對(duì)照組,以上差異提示了骨折人群的骨的抗折彎能力和骨礦鹽含量都降低,骨強(qiáng)度明顯降低,這可能是患者在遭受創(chuàng)傷時(shí)更易發(fā)生骨折的原因[18-19]。
綜上所述,骨代謝指標(biāo)和骨強(qiáng)度指標(biāo)可識(shí)別股骨粗隆間骨折高風(fēng)險(xiǎn)人群并給予及時(shí)的骨質(zhì)疏松治療,不僅可反映骨質(zhì)疏松的骨轉(zhuǎn)換,也反映了骨折愈合過(guò)程中成骨與破骨的偶聯(lián),對(duì)老年股骨粗隆間骨折的指導(dǎo)治療風(fēng)險(xiǎn)預(yù)測(cè)有重要意義[20]。老年股骨粗隆間骨折的預(yù)防要加強(qiáng)看護(hù),注意跌倒防護(hù)工作,排除周圍可能存在的危險(xiǎn)因素,從而降低骨折的發(fā)生率[21]。本研究對(duì)臨床上老年股骨粗隆間骨折患者的手術(shù)預(yù)后和骨質(zhì)疏松的治療具有一定的指導(dǎo)意義。
[1] Maniar HH, Tawari AA, Mookerjee G, et al. Short or long, locked or unlocked nails for intertrochanteric fractures[J]. Tech Orthop, 2015, 30(2): 87-96. DOI:10.1097/bto.0000000000000129.
[2] Huang Y, Zhang C, Luo Y. A comparative biomechanical study of proximal femoral nail (Inter TAN) and proximal femoral nail antirotation for intertrochanteric fractures[J]. Int Orthop, 2013, 37(12): 2465-2473. DOI:10.1007/s00264-013-2120-1.
[3] 葉茂,王奎,鄒毅,等. PFNA與PF-LCP治療老年股骨粗隆間骨折的療效分析[J]. 貴州醫(yī)藥,2014,38(9):828-830.
[4] Chu X, Liu F, Huang J, et al. Good short-term outcome of arthroplasty with Wagner SL implants for unstable intertrochanteric osteoporotic fractures[J]. J Arthroplasty, 2014, 29(3): 605-608. DOI:10.1016/j.arth.2013.07.029.
[5] Li J, Cheng L, Jing J. The Asia proximal femoral nail antirotation versus the standard proximal femoral antirotation nail for unstable intertrochanteric fractures in elderly Chinese patients[J]. Orthop Traumatol Surg Res, 2015, 101(2): 143-146. DOI:10.1016/j.otsr.2014.12.011.
[6] Chang SM, Song DL, Ma Z, et al. Mismatch of the short straight cephalomedullary nail (PFNA-II) with the anterior bow of the Femur in an Asian population[J]. J Orthop Trauma, 2014, 28(1): 17-22. DOI:10.1097/BOT.0000000000000022.
[7] 李金洪,楊友剛,孫紅振,等. 不同手術(shù)方式治療老年人股骨粗隆間骨折的療效研究[J]. 實(shí)用老年醫(yī)學(xué), 2015, 29(1): 55-57.
[8] Schlickewei CW, Rueger JM, Ruecker AH. Nailing of displaced intertrochanteric hip fractures[J]. Tech Orthop, 2015, 30(2): 70-86. DOI:10.1097/bto.0000000000000130.
[9] Guo Q, Shen Y, Zong Z, et al. Percutaneous compression plate versus proximal femoral nail anti-rotation in treating elderly patients with intertrochanteric fractures: a prospective randomized study[J]. J Orthop Sci, 2013, 18(6): 977-986. DOI:10.1007/s00776-013-0468-0.
[10] 王艷,阮華玲,李毅,等. 甲狀腺功能亢進(jìn)患者甲狀腺功能、自身抗體、骨密度及骨代謝指標(biāo)變化分析[J]. 海南醫(yī)學(xué)院學(xué)報(bào), 2016, 22(13): 1418-1421. DOI:10.13210/j.cnki.jhmu.20160315.001.
[11] Hsu CE, Chiu YC, Tsai SH, et al. Trochanter stabilising plate improves treatment outcomes in AO/OTA 31-A2 intertrochanteric fractures with critical thin femoral lateral walls[J]. Injury, 2015, 46(6): 1047-1053. DOI:10.1016/j.injury.2015.03.007.
[12] Shen L, Zhang Y, Shen Y, et al. Antirotation proximal femoral nail versus dynamic hip screw for intertrochanteric fractures: a meta-analysis of randomized controlled studies[J]. Orthop Traumatol Surg Res, 2013, 99(4): 377-383. DOI:10.1016/j.otsr.2012.12.019.
[13] Wilk R, Skrzypek M, Kowalska M, et al. Standardized incidence and trend of osteoporotic hip fracture in Polish women and men: a nine year observation[J]. Maturitas, 2014, 77(1): 59-63. DOI:10.1016/j.maturitas.2013.09.004.
[14] 高長(zhǎng)城,張曉瑞. 四肢骨折延遲愈合患者微循環(huán)與骨代謝指標(biāo)的變化[J]. 海南醫(yī)學(xué)院學(xué)報(bào), 2014, 20(8): 1097-1099. DOI:10.13210/j.cnki.jhmu.20140416.003.
[15] Friedman SM, Clark N, Nicholas JA, et al. Case discussion: hip fracture in a patient on hospice with dementia and anemia[J]. Geriatr Orthop Surg & Rehabil, 2013, 4(1): 26-32. DOI:10.1177/2151458513482939.
[16] Ali AA, Cristofolini L, Schileo E, et al. Specimen-specific modeling of hip fracture pattern and repair[J]. J Biomech, 2014, 47(2): 536-543. DOI:10.1016/j.jbiomech.2013.10.033.
[17] Hélin M, Pelissier A, Boyer P, et al. Does the PFNATMnail limit impaction in unstable intertrochanteric femoral fracture? A 115 case-control series[J]. Orthop Traumatol Surg Res, 2015, 101(1): 45-49. DOI:10.1016/j.otsr.2014.11.009.
[18] 張旭,林偉龍,程群,等. 老年股骨粗隆間骨折患者骨密度及骨強(qiáng)度指標(biāo)的相關(guān)研究[J]. 老年醫(yī)學(xué)與保健, 2014, 20(1): 41-44. DOI:10.3969/j.issn.1008-8296.2014-12.
[19] Yoon PW, Kwon JE, Yoo JJ, et al. Femoral neck fracture after removal of the compression hip screw from healed intertrochanteric fractures[J]. J Orthop Trauma, 2013, 27(12): 696-701. DOI:10.1097/BOT.0b013e31829906a0.
[20] Yoo JH, Kim TY, Chang JD, et al. Factors influencing functional outcomes in united intertrochanteric hip fractures: a negative effect of lag screw sliding[J]. Orthopedics, 2014, 37(12): e1101-e1107. DOI:10.3928/01477447-20141124-58.
[21] Napoli N, Schwartz AV, Palermo L, et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures[J]. J Clin Endocrinol Metab, 2013, 98(2): 659-667. DOI:10.1210/jc.2012-1896.
(本文編輯:林永麗)
Effect of PFNA treatment on bone metabolism and bone strength in senile patients with intertrochanteric fractureRenShisong,HuangBin,LiuHuijun
(DepartmentofOrthopedics,ChongqingFireDepartmentHospital,Chongqing401122,China)
Objective To investigate the effects of PFNA on bone metabolism and bone strength in senile patients with intertrochanteric fracture.Methods Fifty senile patients with intertrochanteric fracture admitted into the hospital from January 2014 to August 2015 were selected as research subjects, and were assigned as the observation group, and another 50 normal old examinees without history of bone fracture recruited from the Physical Examination Center of the hospital were selected as the control group. The patients of the observation group received PFNA treatment. Bone metabolism and bone strength indexes of the observation group were measured both before and after surgery, and bone metabolism and bone strength indexes of the control group were also detected, and then comparisons were made between the 2 groups.Results Before surgery, the levels of PINP, PTH, CTX and OC in the observation group were significantly higher than those in the control group (P<0.05), while the level of 25(OH)D3was significantly lower than that in the control group (P<0.05). However, after surgery, the level of serum PINP[(86.03±27.78)mg/L] in the observation group was significantly higher, as compared with that before surgery [(53.97±26.13)mg/L](P<0.05). The level of PTH[(27.67±11.54)ng/L] was significantly decreased, as compared with that before surgery [(51.22±17.65)ng/L](P<0.05), but it was slightly higher than that of the control group [(36.85±12.86)ng/L](P>0.05). When compared with those before surgery, no significant changes could be seen in the levels of 25(OH)D3, CTX and OC (P>0.05). Before surgery, bone strength indexes, such as the cross section rotation penetration amount (CSMI), bone mineral density (BMD) and the section modulus Z value (Z) of the observation group were all significantly lower than those of the control group (P<0.05), and the buckling ratio (BR) was significantly higher than that of the control group (P<0.05). However, after surgery, the bone strength value of the observation group was slightly decreased, as compared with that before surgery, but without statistical significance (P>0.05).Conclusion After PFNA treatment, bone metabolism of the patients with intertrochanteric fracture was enhanced, but bone strength was not improved. This might be associated with the small amount of peripheral bone loss due to stress shielding during surgery. With this reason, enhanced anti-osteoporosis treatment and related protective measures might be necessary for the prevention of bone fracture.
PFNA; Senile; Intertrochanteric fracture; Bone metabolism; Bone strength
401122 重慶,武警重慶市消防總隊(duì)醫(yī)院骨科(任詩(shī)松);重慶市兩江新區(qū)第一人民醫(yī)院骨科(黃斌);第三軍醫(yī)大學(xué)第三附屬醫(yī)院急救部(劉輝均)
R683.42
A
10.3969/j.issn.1009-0754.2017.01.013
2016-09-20)